- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet
BrainsWay (NASDAQ:BWAY, TASE:BWAY) has announced that it has shipped its 100th Deep Transcranial Magnetic Stimulation (Deep TMS) system to treat major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). As quoted in the press release: Yaacov Michlin, President and Chief Executive Officer of BrainsWay, said, “The shipment of our 100th OCD coil represents an important milestone for …
BrainsWay (NASDAQ:BWAY, TASE:BWAY) has announced that it has shipped its 100th Deep Transcranial Magnetic Stimulation (Deep TMS) system to treat major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
As quoted in the press release:
Yaacov Michlin, President and Chief Executive Officer of BrainsWay, said, “The shipment of our 100th OCD coil represents an important milestone for BrainsWay. Our Deep TMS technology is the only TMS product currently available for OCD patients, and the shipment of OCD helmets to 100 locations across the U.S. allows us to access a large and growing number of patients who are in desperate need of a non-invasive, safe and effective treatment option. Moreover, this key achievement is indicative of the substantial physician demand that exists for additional treatment options for patients with OCD.”
Dr. Ryan Vidrine, Director of OCD program at TMS Health Solutions, said, “OCD is a devastating and debilitating mental health disorder. Integrating the Deep TMS system into my practice has allowed me to further help many OCD patients find relief from the intrusive OCD symptoms they suffer from daily.”
Dr. Geoffrey Grammar, Chief Medical Officer of Greenbrook TMS, added, “By receiving and utilizing BrainsWay’s Deep TMS technology for OCD, we have been able to provide our patients with a novel approach to symptom relief, ensuring they receive the very best care possible.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.